Ingelvac MycoMAX™

The first and only commercially available vaccine for Mycoplasma hyorhinis (Mhr).

Introducing Ingelvac MycoMax™

  • Proven to protect against arthritis, pericarditis, lameness, and peritonitis associated with Mhr1
  • Effectively protects pigs in the nursery phase, when they are most susceptible to Mhr infection resulting
    in clinical disease2—6
  • Facilitates a control program that supports good antibiotic stewardship practices

Product Resources

Contact Info

Boehringer Ingelheim Vetmedica, Inc.

Swine Division
3902 Gene Field Road
St. Joseph, Missouri 64506
Phone 866-638-2226
Fax 816-676-4754

Underdiagnosed

  • The clinical signs of Mhr can be amplified when coinfected with porcine circovirus type 2 (PCV2) or porcine reproductive and respiratory syndrome (PRRS)3,7—​9
  •  Mhr prevalence may be underestimated, as clinical signs of polyserositis can be mistaken for disease associated with Haemophilus parasuis or other bacteria10–14

Uncontrolled

  • Until now, there have been no commercially available Mhr vaccines with demonstrated efficacy against Mhr
    • Current autogenous vaccines may be used, but their efficacy is not evaluated by the USDA
  • When detected in a herd, Mhr is currently treated with antibiotics 

Impactful

CLINICAL SIGNS OF Mhr INFECTION4,5,10—12 EFFECTS OF Mhr INFECTION13
  • Elevation in temperature
  • Lameness
  • Inappetence
  • Difficulty in moving
  • Swollen joints
  • Otitis media
  • Ocular discharge
  • Reduced performance (weight gain and feed conversion)
  • Increased pig variability, mortality, and culling
  • Economic losses

 

 

 

Proven

Vaccination with Ingelvac MycoMAX™ is proven to protect against arthritis, pericarditis, lameness, and peritonitis associated with Mhr.1

Ingelvac MycoMAX™ is the only commercially available Mhr vaccine  supported by a robust challenge model. Current autogenous vaccines do not have to prove efficacy to the USDA.

Unique

The first and only commercially available vaccine for Mycoplasma hyorhinis.

Reliable

Ingelvac MycoMAX™ was proven safe for use in 3-week-old pigs.
A total of 767 pigs in 4 separate locations were administered 2 mL of Ingelvac MycoMAX™ intramuscularly at 3 weeks of age and observed daily for 14 days.1

 

*Immediate reactions (within a 2-hour period following vaccination) were observed in a total of 23 pigs. The increased observations of unthrifty pigs and postvaccination reactions at these sites appeared to be related to air handling in the facilities and concurrent respiratory disease.1

References:

1. BIVI studies 2014245, 2015095, 2016077 published on http://productdata.aphis.usda.gov.
2. Martinson B, Minion FC, Jordan D. Development and optimization of a cell-associated challenge model for Mycoplasma hyorhinis in 7-week-old caesarean-derived, colostrum-deprived pigs. Can J Vet Res. 2018;82:12–23.
3. Clavijo MJ, Murray D, Oliveira S, Rovira A. Infection dynamics of Mycoplasma hyorhinis in three commercial pig populations. Vet Rec. 2017;181(3):68. doi:10.1136/vr.104064.
4. Straw BE, Zimmermann JJ, D’Allaire S, Taylor DJ. Diseases of Swine. 9th ed. Ames, IA: Blackwell Publishing; 2006.
5. Morita T, Ohiwa S, Shimada A, Kazama S, Yagihashi T, Umemura T. Intranasally inoculated Mycoplasma hyorhinis causes eustachitis in pigs. Vet Pathol. 1999;36:174–178.
6. Lin JH, Chen SP, Yeh KS, Weng CN. Mycoplasma hyorhinis in Taiwan: diagnosis and isolation of swine pneumonia pathogen. Vet Microbiol. 2006;115:111–116.
7. Palzer A, Haedke K, Heinritzi K, Zoels S, Ladinig A, Ritzmann M. Associations among Haemophilus parasuis, Mycoplasma hyorhinis, and porcine reproductive and respiratory syndrome virus infections in pigs with polyserositis. Can Vet J. 2015;56:285–287.
8. Chen D, Wei Y, Huang L, et al. Synergistic pathogenicity in sequential coinfection with Mycoplasma hyorhinis and porcine circovirus type 2. Vet Microbiol. 2016;182:123–130.
9. Lee JA, Oh YR, Hwang MA, et al. Mycoplasma hyorhinis is a potential pathogen of porcine respiratory disease complex that aggravates pneumonia caused by porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol. 2016;177:48–51.
10. Rovira A, Clavijo MJ, Oliveira S. Mycoplasma hyorhinis infection of pigs. Acta Sci Vet. 2010;38:S9–S15.
11. Kobisch M, Friis NF. Swine mycoplasmoses. Rev Sci Tech. 1996;15(4):1569–1605.
12. Morita T, Muraki Y, Awakura T, Shimada A, Umemura T. Detection of Mycoplasma hyorhinis in porcine eustachitis. J Vet Med Sci. 1993;55(3):475–477.
13. Murray D. Mycoplasma hyorhinis: not just an incidental finding. 2012 American Association of Swine Veterinarians; March 10–13, 2012; Denver, CO: 457–460.
14. Gomes Neto JC, Gauger PC, Strait EL, Boyes N, Madson DM, Schwartz KJ. Mycoplasma-associated arthritis: Critical points for diagnosis. J Swine Health Prod. 2012;20(2):82–86.